Citadel Advisors LLC purchased a new position in shares of Voyager Therapeutics Inc (NASDAQ:VYGR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 250,384 shares of the company’s stock, valued at approximately $5,155,000. Citadel Advisors LLC owned 0.93% of Voyager Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $270,000. SG Americas Securities LLC acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $577,000. Bank of New York Mellon Corp lifted its holdings in shares of Voyager Therapeutics by 16.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock valued at $1,274,000 after buying an additional 8,633 shares during the period. Birchview Capital LP acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $494,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $1,122,000. 35.97% of the stock is owned by institutional investors and hedge funds.

In other Voyager Therapeutics news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $13.26, for a total transaction of $72,797.40. Following the transaction, the insider now directly owns 16,473 shares in the company, valued at $218,431.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 38,430 shares of company stock worth $562,890 over the last 90 days. 8.00% of the stock is owned by insiders.

Voyager Therapeutics Inc (NASDAQ:VYGR) traded up $0.72 during trading hours on Friday, reaching $14.63. The company’s stock had a trading volume of 696,900 shares, compared to its average volume of 245,625. Voyager Therapeutics Inc has a one year low of $8.10 and a one year high of $25.99.

Several equities analysts recently weighed in on VYGR shares. Wedbush restated a “positive” rating and issued a $31.00 price target (down previously from $36.00) on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research report on Friday, October 27th. They issued a “buy” rating and a $35.00 price target for the company. Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Cowen restated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Finally, ValuEngine lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $26.33.

TRADEMARK VIOLATION WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/12/01/citadel-advisors-llc-purchases-new-stake-in-voyager-therapeutics-inc-vygr.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.